AEZS AEterna Zentaris, Inc. featured news, full reports, and detailed charts
AEterna Zentaris, Inc. (AEZS) Wrap Up:
Æterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization, primarily targeting the North American and European markets. We were incorporated on September 12, 1990 under the laws of Canada. Our registered office is located at 1405 15 -------------------------------------------------------------------------------- du Parc-Technologique Blvd., Quebec City, Quebec, Canada G1P 4P5, our telephone number is (418) 652-8525 and our website is www.aezsinc.com. None of the documents or information found on our website shall be deemed to be included in or incorporated into this annual report. On December 30, 2002, we acquired Zentaris AG, a biopharmaceutical company based in Frankfurt, Germany. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f28%2f0001104659-08-020808.html#FIS_COMPANY_INFORMATION"www.aeternazentaris.com
Founded in 1991
AEterna Zentaris Inc (AEZS:NASDAQ)
LAST $1.00 USD
CHANGE TODAY +0.0176 1.79%
VOLUME 13.8K
As of 10:12 AM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of AEterna Zentaris Inc (AEZS)
|
OPEN
$0.99
|
PREVIOUS CLOSE
$0.98
|
|
|
DAY HIGH
$1.00
|
DAY LOW
$0.98
|
|
|
52 WEEK HIGH
06/1/09 - $3.25
|
52 WEEK LOW
12/4/08 - $0.26
|
|
|
MARKET CAP
63.1M
|
AVERAGE VOLUME 3 mo
95.9K
|
|
|
DILUTED EPS TTM
$-0.94
|
SHARES OUTSTANDING
63.1M
|
|
|
AEZS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
AEZS Top Compensated Officers
Prof. Dr. Juergen Engel Ph.D.
Chief Executive Officer, President, Director,...
Total Annual Compensation: $405.9K
Mr. Juergen Ernst MBA
Executive Chairman and Member of Corporate Go...
Total Annual Compensation: $152.5K
Mr. Dennis Turpin C.A.
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $317.4K
Mr. Paul Blake MB, FRCP, FCP, FFPM
Chief Medical Officer and Senior Vice Preside...
Age: 61
Total Annual Compensation: $355.3K
Dr. Nicholas J. Pelliccione Ph.D.
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $317.3K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for AEterna Zentaris Inc (AEZS)
AEterna Zentaris Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/11/2009
AEterna Zentaris Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported consolidated revenues of $8.6 million compared to $11.0 million for the same period in 2008. This decrease is mainly related to lower royalty revenues having been recognized in 2009 in connection with the monetization of the royalties derived from the company's agreement with Merck Serono. Consolidated net loss was $11.3 million, or $0.19 per basic and diluted share, compared to $13.9 million, or $0.26 per basic and diluted share, for the same period in 2008. This decrease is mainly related to lower comparative R&D expenses, partially offset by lower comparative revenues, less cost of sales. Loss before income taxes was $11.3 million and loss from operations of $9.8 million compared to loss before income taxes of $13.7 million and loss from operations of $12.4 million for the same quarter a year ago. For the nine months, the company reported net loss of $36.8 million or $0.67 per basic and diluted share on revenue of $23.1 million compared to net loss of $45.3 million or $0.85 per basic and diluted share on revenue of $31.2 million for the same period a year ago. Loss before income taxes was $36.8 million and loss from operations of $35.5 million compared to loss before income taxes of $45.1 million and loss from operations of $46.1 million for the same period a year ago.
AEterna Zentaris Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/11/2009
AEterna Zentaris Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net cash used in operating activities of $13,120,000 compared to $13,240,000 for the same period of last year. Purchases of property, plant and equipment was $398,000 compared to $281,000 for the same period of last year. For the nine months, the company reported net cash used in operating activities of $13,984,000 compared to $40,861,000 for the same period of last year. Purchases of property, plant and equipment was $467,000 compared to $1,342,000 for the same period of last year.
AEterna Zentaris Inc., Q3 2009 Earnings Call, Nov-11-2009
11/4/2009
AEterna Zentaris Inc., Q3 2009 Earnings Call, Nov 11 2009
AEZS Competitors
| Company | Last | Change |
| Akela Pharma Inc | C$0.18 CAD | 0.00 |
| C$0.09 CAD | 0.00 | |
| EntreMed Inc | $1.08 USD | -0.02 |
| Spectrum Pharmaceuticals Inc | $4.64 USD | -0.14 |
| Theratechnologies Inc | C$2.85 CAD | +0.07 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | AEZS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.6x |
|
|
AEZS |
||
|
AEZS transactions
| Type Date |
Target |
|
Private Placement
October 19, 2009 |
-- |
|
Private Placement
June 19, 2009 |
-- |
|
Merger/Acquisition
June 5, 2009 |
Ardana Bioscience Ltd., AEZS-130 |
More Recent News About AEterna Zentaris, Inc.
More news for AEZS
AEterna Zentaris Receives US$5.5 Million from Institutional Investors
QUEBEC CITY, Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS - News; TSX: AEZ - News), (the "Company") a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$5.5 million of units comprised of common shares and common share purchase warrants to certain institutional investors. AEterna Zentaris received net proceeds of approximately US$5.1 million after deducting placement agent fees and other offering expenses. All of the common shares and warrants were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including clinical development of the Company's leading compounds. Juergen Engel, Ph. D., President and CEO of AEterna Zentaris stated, "We are very pleased with this vote of confidence from targeted specialized institutional investors. In addition, completing this financing provides us with additional funds that will help us to continue to further strengthen and advance our promising pipeline."As of October 23, 2009 and after issuing 4,583,335 common shares at the closing of the o...Click here to read the whole Article (external link)
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian cancer. QUEBEC CITY, Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ - News; Nasdaq: AEZS - News; the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer. In a personalized healthcare approach, the study selected patients with tumors expressing LHRH receptors, the key element in the targeting mechanism of AEZS-108. Under coordination by Prof. Gunter Emons, MD, Chairman of the Department of Obstetrics & Gynaecology at the University of Gottingen, Germany, this open-label, multi-center and multi-national Phase 2 study 'AGO-GYN-5' is being conducted by the German AGO Study Group (Arbeitsgemeinschaft Gynakologische Onkologie / Gynaecological Oncology Working Group; ...Click here to read the whole Article (external link)
AEterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
All amounts are in U.S. dollars QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009. Third Quarter 2009 Highlights - July 7, 2009. Publication in Proceedings of the National Academy of Sciences, of new data supporting the use of AEZS-123 for the treatment of alcohol dependence that involves ghrelin. - August 3, 2009. The Company's licensee partner for perifosine in North America, Keryx Biopharmaceuticals ("Keryx"), disclosed that it had reached an agreement with the FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial for multiple myeloma. - August 17, 2009. Disclosure of results for two Phase 3 studies with cetrorelix in benign prostatic hyperplasia ("BPH"). The efficacy study Z-033 did not achieve its primary endpoint. Results from the safety study Z-041 were positive and exhibited a similar level of efficacy as the previously disclosed Phase 2 study results. - September 16, 2009. Disclosure that Keryx received Orphan Drug designation from the FDA for perifosine for multiple myeloma. - September 21, 2009. Disclosure of Phase 1 study results with AEZS-112 in advanced solid tumors or lymphoma showed prolonged courses of stable disease, excellent tolerability and potential for long-term use as a combination treatment for cancer. - September 30, 2009. Disclosure of results for the Thorough QT Z-043 ("TQT") study, which is part of the cetrorelix pamoate clinical development in BPH. The study met its primary endpoint. Subsequent to Quarter-End ...Click here to read the whole Article (external link)
Q3 2009 Aeterna Zentaris Inc. Earnings Release - Before Market Open
Earnings Announcements for Wednesday, November 11CompanySymbolTimeConferenceCallACEGAS SPAAEG.MITime Not SuppliedADLINK INTERNET AGLKI.FTime Not SuppliedAdvance Auto PartsAAPAfter Market CloseListenAEGEAN MARINE PETROLEUM NETWORK INCANWAfter Market CloseListenAeterna Zentaris Inc.AEZSBefore Market OpenAlliant Techsystems Inc.ATKAfter Market CloseListenALLOT COMMUNICATIONS LTDALLTTime Not SuppliedListenAmerican BiltriteABLAfter Market CloseAmerican DG Energy Inc.ADGEBefore Market OpenAmeriGas PartnersAPUBefore Market OpenListenANATOLIA MINERALS DEV LTDALIAF.PKTime Not SuppliedApplied MaterialsAMATAfter Market CloseListenARACRUZ CELULOSE S AARABefore Market OpenARCADIS NVARCVF.PKBefore Market OpenArden GroupARDNATime Not SuppliedArotech CorporationARTXAfter Mar...Click here to read the whole Article (external link)
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The clinical data to be presented demonstrates the potential safety and efficacy of KRX-0401 in the treatment of patients with relapsed/refractory multiple myeloma. Details on the Abstract selected for poster presentation are as follows: Abstract #: 1869 TITLE: Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Updated Phase I/II Trial Results Lead Author: Paul Richardson, MD Session Name: Myeloma - Therapy, excluding Transplantation Poster I Date: Saturday, December 5, 2009 Presentation Time: 5:30 PM - 7:30 PM Location: Ernest N. Morial Convention Center, Hall E Poster Board no.: I-891 This abstract became available for viewing yesterday on the American Society of Hematology website (...Click here to read the whole Article (external link)
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS - News; TSX: AEZ - News; the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News), its partner and licensee for perifosine (KRX-0401) in the North American market, will present data from a Phase 1/2 clinical trial of perifosine in combination with bortezomib (+/- dexamethasone), during a poster presentation session at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The clinical data to be presented demonstrates the potential safety and efficacy ...Click here to read the whole Article (external link)
New Star Analyst Rankings for AEterna Zentaris, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
Would you like to leave a comment about AEterna Zentaris, Inc. AEZS
Find out what social network information about AEterna Zentaris, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides AEterna Zentaris, Inc. there is more great information available at Realpennies.com